NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 6.9% After Insider Selling

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)’s stock price dropped 6.9% during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $24.25 and last traded at $23.8690. Approximately 167,541 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 1,045,328 shares. The stock had previously closed at $25.63.

Specifically, Director John W. Smither sold 1,600 shares of NewAmsterdam Pharma stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $25.32, for a total value of $40,512.00. Following the completion of the transaction, the director owned 8,760 shares of the company’s stock, valued at $221,803.20. This trade represents a 15.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Royal Bank Of Canada decreased their price objective on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. BMO Capital Markets initiated coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $49.73.

Key NewAmsterdam Pharma News

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $52 price target. Other analysts also maintain positive views, including BMO Capital Markets at $58, Jefferies at $45 and RBC at $50, supporting the longer-term outlook for NAMS. HC Wainwright rating report
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. This suggests short selling is not a meaningful explanation for the recent decline, although the data may reflect an incomplete or anomalous report. NewAmsterdam Pharma market data
• Neutral Sentiment: Analyst reports discussing NAMS alongside Amgen, Dyne Therapeutics and Ionis Pharmaceuticals did not identify a new company-specific catalyst. Broader healthcare-sector commentary may influence sentiment but provides limited direct information about NewAmsterdam’s business. Healthcare analyst report
• Negative Sentiment: Director John W. Smither sold 1,600 shares for approximately $40,512, reducing his direct holdings by 15.44%. Although the sale may have been for personal reasons, it can reinforce investor caution during a period of market weakness. SEC insider transaction filing
• Negative Sentiment: NAMS reached a new one-year low following the insider-sale disclosure, signaling continued technical and investor-pressure concerns. The company also remains loss-making; its latest quarterly EPS missed expectations, and analysts forecast a full-year loss of about $1.82 per share. New one-year low report

NewAmsterdam Pharma Trading Down 4.1%

The company has a market cap of $2.61 billion, a price-to-earnings ratio of -10.12 and a beta of 0.09. The firm’s 50-day moving average price is $28.84 and its 200 day moving average price is $31.27.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. Analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NewAmsterdam Pharma

Institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN grew its stake in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares in the last quarter. KBC Group NV purchased a new stake in shares of NewAmsterdam Pharma during the first quarter worth about $37,000. Navalign LLC bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $46,000. AdvisorNet Financial Inc purchased a new position in shares of NewAmsterdam Pharma during the first quarter valued at about $82,000. Finally, Empowered Funds LLC bought a new position in NewAmsterdam Pharma in the fourth quarter worth $85,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.